Is ZNTL or ZYME more undervalued in 2026?

CirclFi compares Zentalis Pharmaceuticals, Inc. (ZNTL) and Zymeworks Inc. (ZYME) using 13 institutional-grade valuation models. ZNTL has a Quality of Company score of 5.0/10 while ZYME scores 7.2/10.

Which is a better buy — ZNTL or ZYME?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ZNTL and ZYME valuations compare?

ZNTL at $4.05 and ZYME at $25.48 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ZNTL vs ZYME Valuation Comparison 2026 — Intrinsic Value Analysis

ZNTL

Biotechnology

Zentalis Pharmaceuticals, Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$4.05

Last close

Models

10/13

Active

ZYME

Biotechnology

Zymeworks Inc.

Quality

7.2

out of 10

Value Trap

SAFE

Price

$25.48

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	ZNTL Fair Value	ZNTL Upside	ZYME Fair Value	ZYME Upside
Bayesian DCF	Intrinsic	$1.11	-72.5%	$6.77	-73.4%
Earnings Power Value	Intrinsic	—	—	$13.29	-52.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.99	-26.3%	$3.36	-86.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ZNTL vs ZYME — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ZNTL vs ZYME — Which Stock Is More Undervalued?

ZYME scores higher with a 7.2/10 quality rating vs ZNTL's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Zentalis Pharmaceuticals, Inc. (ZNTL) and Zymeworks Inc. (ZYME) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ZNTL currently trades at $4.05 with a QOC of 5.0/10, while ZYME trades at $25.48 with a QOC of 7.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).